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Abstract— Human diseases caused by protozoan 
parasites are renowned for their high rates of morbidity 
and mortality worldwide. Some examples include African 
trypanosomiasis or sleeping sickness, American 
trypanosomiasis or Chagas disease, leishmaniases, 
malaria and babesiosis. These infections tend to follow a 
chronic rather than an acute course with lifelong 





cell subset, appear to control 
the immune competence of host response triggered by the 
presence of parasites, promoting homeostasis and 
protecting the host from collateral tissue damage whilst 
allowing parasite persistence. To date, there is still 
considerable controversy on the characteristics and 
function of these cells when induced during different 
protozoan infections, evidencing the need of further 
research. Therefore, this review aims to provide a 
comprehensive overview about Treg cells development, 
phenotype determination and general functions. The 
above pathologies were used as selected examples to 
discuss the role of Treg cells during protozoan infections. 
Understanding of the mechanisms that contribute 
towards homeostasis and the survival of the host, and 
simultaneously allow the persistence of the pathogen, 
may yield important insights for new strategies of 
prophylaxis and therapy. 
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ROTOZOAN parasites are the causative agents of many 
insect-borne infections that continue to represent major 
threats to human health worldwide [1]. In developing 
countries, these diseases constitute an important cause of 
morbidity and mortality [2, 3], mainly due to the limited 
availability of therapies and lack of affordable and effective 
vaccination strategies [4, 5]. Some examples include African 
trypanosomiasis or sleeping sickness, American 
trypanosomiasis or Chagas disease, leishmaniasis, malaria 
and babesiosis, which are caused by Trypanosoma brucei, 
Trypanosoma cruzi, Leishmania spp., Plasmodium spp., and 
Babesia spp., respectively.  
In immunocompetent individuals, despite the existence of 
a strong anti-protozoan response, the immune system seems 
to allow the persistence of a small number of parasites, with 
parasite load persisting for a long time at a tolerable level. 
Thus, the infections tend to follow a chronic rather than an 
acute course [6], as sterile immunity is difficult to achieve, 
which could be beneficial for the host in endemic areas, 
leading to the establishment of protective cell memory [7]. In 
addition, since these parasites are able to establish a 
persistent infection, situations that disturb the immune 
system, such as malnutrition, advanced age or co-infections 
can lead to the reactivation of these infections. More recently, 
an emergent problem has arisen in humans regarding 
acquired immunodeficiency, caused for example by Human 
Immunodeficiency Virus (HIV) or by specific immune 
suppressor treatments, responsible for an increase of immune 
compromised individuals. In these individuals the normally 
asymptomatic or latent protozoan infections can be triggered 
and cause significant clinical disease (reviewed by Mendez et 
al. [8]).  
Over recent years, the concept of a self-regulating immune 
system has been researched extensively. The potency of the 
host immune response triggered by the presence of parasites 
has to be strongly counterbalanced by regulatory responses 
that control the extent of auto-reactive responses and promote 
homeostasis during infection. It is therefore important to 
achieve effective parasite control whilst protecting the host 
from tissue damage, preventing clearance of infection [6, 9, 
10]. If uncontrolled by the regulatory mechanisms, the 
induction of a strong immune response can cause 
immunopathology and even lethality [9]. Amongst others, 
one such mechanism involves the generation of 
immunosuppressive regulatory T cells (Treg) [11]. Under 
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normal conditions, Treg cells can regulate the innate and 
adaptive immune responses and control the excessive and 
misdirected response mediated by effector T cells [12, 13]. 
This study aims to review the published information about 





 Treg cell subset, in maintaining homeostasis 
during the immune response triggered by the presence of 
protozoan parasites responsible for trypanosomiasis, 
leishmaniasis, malaria and lastly babesiosis. In order to 
understand how the regulatory mechanisms exert their action, 
a brief overview describing the development of Treg cells, 
phenotype determination and general functions is provided. 
Finally, an understanding of the mechanisms by which 
regulation of the immune system ensures homeostasis and 
avoids severe immunopathology of the host by suppressing 
immune response, and simultaneously allows persistence of 
the pathogen, may yield important evidences to incorporate 
into the design and development of novel strategies for 
prophylaxis and therapeutics.  
 
II. THE ROLE OF REGULATORY CD4+CD25+ T CELLS: AN 
OVERVIEW 
A. Regulation of the immune system: Regulatory T cells  
A large and ever increasing body of data is accumulating 




 T cells, 
also known as natural or endogenous regulatory T cells 
(nTreg). In healthy humans, these cells comprise 2-4% of 
peripheral CD4
+
 T cells, whereas in mice represent 5 to 10% 
[14]. This subset of cells is able to prevent autoimmunity 
through inhibition of the activation and expansion of 
autoreactive T cells and actively maintain peripheral 
tolerance [12, 15, 16]. Treg cells are able to recognize 
self-antigens in autoimmunity, as well as exogenous antigens 
in hypersensitivity and infectious diseases [17, 18]. 
 
B. Development of regulatory T cells 





 thymocyte. Within the thymus, nTreg cells 
develop from naïve CD4
+
 thymocytes following exposure to 
antigen and self-stimulation with cytokines [19]. This yields 
a fully functional mature subset of T cells which migrate to 
the periphery and are immediately able to suppress 
auto-reactive conventional T cells. nTreg cells exhibit a 
characteristic immune phenotype which include the 
expression of the transcription factor forkhead box P3 
(FoxP3) [20] and of the surface markers cytotoxic 
T-lymphocyte antigen 4 (CTLA-4), CD28, 
glucocorticoid-induced TNF receptor-related protein (GITR) 
and the interleukin (IL)-2 receptor α (CD25) [21]. In addition 





) move to peripheral sites and undergo 
maturation to produce further distinct subsets. Naïve CD8
+
 T 
cells develop into a minor Treg population, which may or 
may not express FoxP3, following exposure to foreign or 
self-antigen [22]. By contrast, the naïve CD4
+
 cells that have 
migrated are induced through exposure to a low dose of 
antigen alongside stimulation with the cytokines IL-2 and 
transforming growth factor (TGF)-β [23, 24]. These cells 
commonly referred to as “induced” Treg cells (iTreg) express 
FoxP3 and maintain peripheral tolerance [24]. 
Mucosa-associated lymphoid tissues (MALT) are further 
sites where the development and expansion of distinct 
subsets of Treg cells can be driven by cytokines. 
MALT-resident antigen presenting cells (APC) secrete 
IL-10, TGF-β or a “cocktail” of IL-2/TGF-β/retinoic acid, 
which, respectively, leads to the differentiation of naïve 
CD4
+
 T cells into regulatory T cells of type 1 (TR1) [25], T 
helper 3 cells (Th3) [26] and iTreg cells [27]. When exposed 
to the altered microenvironment created under certain 
pathological conditions, Treg cells can lose FoxP3 
expression and consequently, their ability to suppress other 
cells, behaving like conventional effector T cells. All these 
potential outcomes generate an enormous plasticity within 
the peripheral pool of T cells [28]. In addition, the in vitro 
stimulation of Treg cells with IL-6 causes the loss of FoxP3 
and differentiation into T helper 17 cells (Th17) that secrete 
IL-17 [29].  
 
C.  Function of Regulatory T cells  
The major function of Treg cells is to maintain immune 
cell homeostasis. This is achieved via four alternative 
mechanisms that negatively regulate conventional T cells and 
dendritic cells (DC), although other major groups of immune 
cells such as natural killer (NK) cells can also be inhibited. 
One such mechanism involves the use of suppressive 
cytokines or other molecules, which are either secreted or 





 effector T cells is achieved 
through exposure to TGF-β attached to the Treg cell 
membrane [1]. Treg cells can also secrete IL-10, IL-35 or 
TGF-β, which induce cell cycle arrest in effector T cells 
located nearby [2]. The secretion of IL-10 can also block 
co-stimulation of DC. Furthermore, galectin-1 can be 
released by Treg cells to induce apoptosis in adjacent T cells 
expressing the CD45 and CD43 glycoprotein receptors.  
A second mechanism adopted by CD8
+
 Treg cells also 
induces apoptosis in either T cells or DC. The secretion of 
perforin molecules creates pores in the membranes of 
effector T cells or DCs and granzymes (A or B) giving origin 
to the cascade of caspases, ending in programmed cell death 
(reviewed by Sakaguchi et al. [2]).  
A third mechanism of Treg-mediated suppression involves 
disrupting the metabolic function of target cells. There are 
three well-defined ways by which this is achieved. Firstly, 
Treg cells are capable of depriving conventional T cells of a 
source of IL-2, attenuating their proliferation, [32] leading to 
apoptosis. Secondly, Treg cells can initiate indirect apoptosis 
of T cells via a DC intermediate. In this situation, CTLA-4 
expressed on the surface of Treg cells binds to either CD80 or 
CD86 molecules found on DC, upregulating indoleamine 
2,3-dioxygenase production in DC [3]. This enzyme 
catabolises tryptophan and the simultaneous depletion of this 
essential amino acid starve nearby T cells, directing them to 
apoptose. Finally, the CD39 and CD73 glycoproteins on the 
surface of Treg cells synthesize adenosine from adenosine 
triphosphate in the extracellular space [4]. Both DC and 
conventional activated T helper cells express the adenosine 
receptor A2AR, and following binding of the nucleoside, are 
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inhibited. In the case of DCs, their maturation and ability to 
stimulate T cells is suppressed. Helper T cells are suppressed 
by adenosine through its effect on their production of 
cytokines. A significant reduction in the secretion of IL-2, 
IL-4, tumor necrosis factor (TNF)-α and interferon gamma 
(IFN)-γ is observed due to decreased transcript stability in 
these cells [4].  
A fourth mechanism of FoxP3
+
Treg cells mediated 
suppression consists of alternative ways to target DC, of 
which three different contact-dependent mechanisms have 
been defined. Firstly, FoxP3
+
 Treg cells use their T-cell 
receptors to engage class II molecules of major 
histocompatibility complex (MHCII) on the surface of DC. 
Coupled with the binding of Neuropilin-1 on the Treg cell 
surface to its similar receptor found in DC, prolongs their 
interaction at the immunological synapse, outcompeting 
nearby T helper cells and causing the suppression of APC [5]. 
A second way implies targeting of DC and inhibition of cell 
maturation. Here, the lymphocyte activation gene 3 
transmembrane protein expressed by FoxP3
+
 Treg cells binds 
to MHCII on the surface of DC, inhibiting their activation 
[6]. The third alternative DC-targeting mechanism employed 
by iTreg cells uses the CTLA-4 receptor present in 
membrane. This constitutively expressed protein binds to 
CD80/CD86 molecules on the DC surface which leads to 
their internalization in a process termed trans-endocytosis [7] 
inhibiting DC function. 
 
D. Regulatory T cells preventing autoimmunity 
Treg cells have been identified as the key players in a 
number of important immune responses in vivo. One such 
example is the prevention of autoimmunity whereby Treg 
cells suppress the activation of the effector T cells. In mice 
depleted of Treg cells, autoimmunity prevails, however, the 




 T cell subset prevents 
autoimmunity [8]. Nonetheless, more recent evidence has 
indicated that effector T cells are able to resist this 
suppression. For example, in patients with rheumatoid 
arthritis [9] and multiple sclerosis [10], Treg-mediated 
suppression is lost and peripheral blood Treg cell counts are 
similar between patients and healthy controls. A recent study 
has deciphered the underlying mechanism responsible for 
this absence of regulation. In patients with juvenile idiopathic 
arthritis, resistance to Treg suppression is mediated by 
hyperactivation of protein kinase B in effector T cells at the 
site of inflammation [11]. This is a direct consequence of 
these cells being stimulated by IL-6 and TNF-α, though other 
cytokines and CD28 signaling may also contribute [11].  
E.  Regulatory T cells promoting chronic infection  







 Treg cells is the establishment of chronic 
infection. A broad spectrum of pathogens, including bacteria 
(Helicobacter pylori), fungi (Candida albicans), protozoan 
(Leishmania major) and virus (hepatitis C virus) has been 
shown to become manifested as persistent human infections 
because the action of Treg cells [12]. 
Most protozoan infections follow a chronic rather than an 
acute course, with the parasite persisting for a long time [13, 
14]. To achieve effective parasite control, whilst protecting 
the host from tissue damage, a fine balance needs to be 
achieved by Treg cells to limit the potency of the host 
immune response. An overabundance of Treg cells or their 
overactivation may cause immunopathology and lethality 
and, also allow pathogens to become transmitted more easily 
[15]. Somewhere between these two extremes exists a 
balance between the immunosuppressive activity of Treg 
cells and effector T cells. Although the host may benefit from 
milder  pathology and be protected from disease, this can be 
where infections persist and become established as chronic 
diseases [12].  
Despite the complex interactions between parasites and 
their hosts, considerable progress has been made to 
understand the involvement of Treg cells during many 
protozoan infections. Though their role is not very well 
defined, some illustrative examples of protozoan infections 
that involve Treg cells in their pathogenesis are reviewed. 
 
III. THE ROLE OF REGULATORY CD4+CD25+ T CELLS SUBSET 
IN HOST HOMEOSTASIS DURING PROTOZOAN INFECTION: 
LEISHMANIASIS, TRYPANOSOMIASIS, MALARIA AND 
BABESIOSIS 
A.  Leishmaniasis 
Leishmaniasis, caused by Leishmania spp., is a serious 
public health issue with a worldwide distribution [16]. 
Leishmania includes a broad genus of obligatory intracellular 
flagellate protozoa that infect mononuclear phagocytes [17].  
Leishmania uses a very distinct strategy to preserve their 
life cycle based on just two morphological forms: the 
amastigote, a non-flagellated form that resides intracellularly 
within the mononuclear cells of their mammalian hosts, such 
as humans, dogs and rodents, among others; and the 
promastigote, an extracellular flagellate form that develops in 
the intestinal tract of sandfly. The vector, a female sandfly of 
the genus Phlebotomus and Lutzomyia ingests amastigote 
forms while feeding on the mammal host and, within the 
midgut, the amastigote forms develop into infective procyclic 
promastigote forms [18]. In a subsequent blood meal, the 
female sandfly deposits the promastigote forms into a 
mammalian host [19]. Shortly after inoculation, these 
promastigote forms are phagocyted by dermal macrophages 
and/or DC at the site of the bite and, inside phagolysosomes, 
they transform into amastigotes and replicate [17, 19]. The 
excess of parasite load inside the cells due to parasite 
replication within the phagolysosome leads to cell lysis and 
the free amastigotes will then infect new phagocytes. The life 
cycle is completed when the female sandflies ingest infected 
phagocytes [18].  
Leishmania spp. are responsible for a wide variety of 
disease presentations, namely the polymorphic cutaneous 
forms, the rare mucocutaneous and the fatal disseminated 
visceral form [17]. Clinical symptoms are caused by parasite 
dispersion within macrophages by nasopharyngeal mucosa 
and by organs of the mononuclear phagocytic system 
(reviewed by Campanelli et al. [20]). 
Cutaneous leishmaniasis can be caused by L. major, L. 
tropica and L. aethiopica in Africa, Middle East and parts of 
Asia [17], and by several Leishmania species of the 
braziliensis and mexicana complexes in central and South 
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America. In most vertebrate hosts, the infection is 
characterized by a period of latency, followed by lesion 
development that may not ulcerate [15].  
During infections caused by Leishmania spp., in particular 
cutaneous leishmaniasis, regulation of the immune response 
is important for two reasons: firstly, it allows the persistence 
of the parasite within the host cells after clinical resolution; 
and secondly, contributes to the establishment of the host cell 
memory [21], and eventually protection against re-infection. 
After successful chemotherapy or self-cure, low numbers of 
viable parasites will persist within lymphoid tissue and at the 
skin lesions, giving rise to latent infections [22, 23]. 
Macrophages and DCs were found to harbor persistent 
parasites within the lymph nodes [24, 25]. This latent 
infection can be reactivated as a result of 
immunosuppression, environmental factors or with advanced 
age (reviewed by Mendez et al. [23]) and give rise to visceral 
leishmaniasis and mucosal leishmaniasis (reviewed by 
Belkaid et al. [22]). The equilibrium established during 
chronic infection might reflect both parasite and host survival 
strategies. From the host point of view, the inability to 
achieve an absolute cure is beneficial, especially if they 
reside in endemic areas, where an efficient memory response 
is important [21, 26].  





 subset, have a fundamental role 
controlling the outcome of Leishmania infection, among 





 Treg cells are essential for the development and 
maintenance of a persistent cutaneous infection with L. major 
in resistant C57BL/6 mice. Treg cells rapidly accumulated at 
primary sites of infection, suppressing the capacity of the 
immune response to completely eliminate the parasite [26]. 





cells were found in chronic skin lesions caused by L. 
braziliensis [20].  
Treg cells can also control the intensity of the memory 
response and the balance between these cell subset and 
effector T cells seems to affect the course of the disease. 





 Treg cells increased at sites where the 
infection was reactivated. Similarly, the presence of Treg 
cells during human L. major infection was confirmed to be 
higher in chronic lesions in comparison to effector T cells, 
which in turn were more frequent in active lesions [27]. 
Overall, results show that the balance between Treg and 
effector T cells determines the outcome of infection. The 
balance tendency towards Treg cells in chronic infections and 
their presence at the time of memory response might be the 
cause of long-lasting disease and a decisive factor governing 





 Treg cells produce the immunosuppressive 
cytokine IL-10 that is now known to play a role in parasite 
persistence. Belkaid et al. [22] investigated the factors that 
control L. major persistence and reactivation after clinical 
cure. Comparing acute and chronic infections in C57BL/6 
and C57BL/10 wild-type mice and in IL-10 knockout mice, 
they have found that IL-10 is required for L. major 
persistence. During the chronic stage, IL-10 deficient mice 
and wild-type mice treated with anti-IL-10 antibody achieved 
sterile immunity, with complete clearance of parasites from 
the skin. Kane and Mosser [28] confirmed the role of IL-10 in 
cutaneous leishmaniasis. After L. major infection, it was 
shown that genetically susceptible BALB/c mice lacking 
IL-10 were able to control disease progression, developing 
relatively small lesions; however, BALB/c wild-type mice 
developed progressive non-healing lesions with numerous 





 Treg cells was confirmed in C57BL/6 mice 
infected with a strain of L. major responsible for non-healing 
dermal lesions [29]. The results support the fact that IL-10 
exerts a potent inhibitory effect on macrophage activation, 
especially at the level of cytokine production [30] and 
leishmanicide capability [31, 32]. 
Treg cells can downregulate both protective T helper (Th) 
1 and pathogenic Th2 responses and the balance of Th1 and 
Th2 cell functions is critical for the outcome of cutaneous 
leishmaniasis. Belkaid et al. [26] have shown that in 




 Treg cells suppress 
Th1 cells, preventing the parasites from being completely 
eliminated whilst in susceptible mice, Treg cells prevent the 
early appearance of lesions and lead to a better control of 




 Treg cells can also 
suppress the differentiation of Th2 cells and prevent the 
development of progressive lesions caused by L. major in 
susceptible mice [33]. In addition, after L. major infection, 




 Treg cells, in 
comparison with wild-type BALB/c mice, develop more 





 Treg cells downregulate IL-4 secretion 
by CD4
+
 T cells, thus affecting Th2 cell maturation [34].  
Visceral leishmaniasis, commonly known as Kala-azar, is 
caused by L. donovani in South Asia and Africa and by L. 
infantum in the Mediterranean region, the Middle East, Latin 
America and some areas of Asia [17]. Parasite replication 
within macrophages with further spreading to other locations 
of the mononuclear phagocytic system is responsible for 
disease pathogenesis [16].  




 Treg cells also 
seem to play a role during the course of L. infantum infection, 
promoting parasite persistence and the establishment of 
chronic infection. After experimental infection of susceptible 





 Treg cells rapidly expand in infected lymph 
nodes and spleen cells along with an increased parasite load. 
In addition to which, several characteristic Treg cell surface 
markers (FoxP3, CD25, GITR, CD103) were concurrently 
transcribed at 7 days after infection, underlining the 
involvement of these cells during this infection. At this 





 effector T cell subset harvested from 
the lymph nodes and splenocytes of infected mice was 
observed. This suggests that Treg cells undergoing expansion 
during this stage of the infection were suppressing the Th2 
effector cell population. A statistically significant increase in 




 T cells was also 
seen at 7 days after infection which may indicate the TR1 
regulatory subset contribute, in part, to the suppression of 
effector T cells [16].  
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B.   Trypanosomiasis 
Trypanosoma brucei gambiense and T. brucei rhodesiense 
are flagellate parasites responsible for the African 
trypanosomiasis in humans, also known as the sleeping 
sickness [35]. T. brucei gambiense is frequently found in 
West and Central Africa, being responsible for a chronic 
form of the disease that can develop over months and years. 
T. brucei rhodesiense, a less common species, is often found 
in East Africa and is associated with severe acute forms of the 
disease. African trypanosomiasis caused by T. b. rhodesiense 
is a zoonotic disease, in which asymptomatic wild and 
domestic animals act as reservoirs [36].  
African trypanosomes go through several morphologically 
distinct phases during their life cycle. The infection is 
initiated when a haematophagous arthropod, the tsetse fly 
(genus Glossina), feeds on a vertebrate host. During the 
blood meal, the tsetse fly deposits metacyclic 
trypomastigotes in the dermal connective tissue of the host. 
The parasites rapidly reach the lymphatic and blood 
circulation, replicate and develop into trypomastigotes 
spreading to other locations [37]. The tsetse fly becomes 
infected during feeding from an infected host. Then the 
trypomastigotes replicate in the midgut and develop into 
procyclic trypomastigotes. They subsequently develop into 
migrating epimastigotes that attach to the salivary glands, 
differentiating into metacyclic trypomastigotes to continue 
the parasite life cycle in a subsequent meal [36].  
African trypanosomes are very unusual amongst protozoan 
parasites in that they only have parasitic extracellular stages 
in the vertebrate host, persisting for extended periods of time 
in the blood [37]. This characteristic makes them vulnerable 
to antibody-mediated immune destruction and around 99% of 
the circulating parasites are cleared from the blood by 
macrophages [14, 35].  
Similarly to what has been described for Leishmania 
infections, some groups have shown that Treg cells are 
present and might play a pivotal role controlling the outcome 
of African trypanosomiasis and the persistence of the 
parasite. In trypanosomiasis, the persistent infections are 
accompanied by a profound immunosuppression (reviewed 
by Adalid-Peralta et al. [38]).  
During African trypanosomiasis, it has been reported that 
the expansion of Treg cells is responsible for parasite 
tolerance from the moment of establishment of infection and 
continuing during chronic stage [38].  
Guilliams et al. [39] showed that Treg cells influence the 
outcome of the disease in trypanotolerant C57BL/6 mice. 
C57BL/6 mice are considered tolerant to the disease when 
infected with T. congolense, controlling the first peak of 
parasitemia and developing a chronic and systemic infection. 







 Treg cells within the CD4
+
 T cell 
population, both in the liver and spleen of infected mice. The 
expansion was verified after the first peak of parasitemia 
(acute phase) and during the chronic phase. It was also 




 Treg cells 





 T effector cells, as well downregulating the 
activation of macrophages. When Treg cells were depleted, 
using an anti-CD25 monoclonal antibody (IL-2Rα), the 
trypanotolerant C57BL/6 resistant mice decreased their 
survival rate with augmented liver necrosis and consequent 
loss in parasite clearance capacity [39]. These results show 
that Treg cells play a fundamental role in the downregulation 
of Th1 immune response during the chronic stage of 
infection, preventing injury to the liver, maintaining its 
parasite clearance function, and contributing to the 
development of the trypanotolerant phenotype in T. 
congolense-infected mice [39]. Finally, Treg cells may not 
only influence the local suppressive activity and the delay of 
the immune response in T. congolense infections, but also the 
secretion of IL-10. In turn, it is possible that IL-10 generate a 
beneficial suppressive environment for the expansion of 
antigen-specific Treg cells.  
More recently, the same group has shown that sustained 
inflammation responsible for tissue damage and reduced 
survival of T. brucei-infected C57BL/6 mice undergoing a 
pathogenic infection was associated with the absence of Treg 
cell expansion [40].  




 Treg cells to 
the survival rate and parasite persistence during 
Trypanosoma spp. infections is still controversial. Studies 






 Treg cells prevent an 
early protective response in T. congolense-infected 
susceptible BALB/c mice. After an optimal dose of 
anti-CD25 antibody, infected mice did not develop 
parasitaemia, eliminated all parasites and showed no signs of 
disease [41]. 
American trypanosomiasis or Chagas disease is caused by 
the obligate intracellular parasite Trypanosoma cruzi [36].  
Insects of the family Reduviidae become infected with the 
trypomastigote form when take a blood meal from an infected 
mammalian host. Replicative non-infective epimastigotes 
develop into trypomastigotes in the insect midgut. During the 
bite, the insect normally urines and defecates leading to the 
release of infective metacyclic trypomastigote forms [18]. 
The parasite then has access to host tissues through a 
continuity lesion on the skin caused by the insect, or through 
intact mucosae or conjunctivae [42]. Humans can also be 
infected by the oral route with subsequent invasion of the 
stomach epithelium or through the transplacental route 
(reviewed by Walker et al. [18]). T. cruzi is internalized either 
by nucleated host cells or phagocytized by macrophages and 
dendritic cells, with further proliferation into non-flagellated 
amastigotes inside cells from the skeletal muscle or 
myocardium [42]. After replication, amastigote forms are 
triggered to differentiate into motile flagellated 
trypomastigotes [18]. The infected cells rupture releasing 
new trypomastigotes into the blood and lymph, with 
consequent invasion of new cells [42]. The life cycle is 
complete when trypomastigotes or amastigotes, also known 
to be infective, are ingested by the insect during a blood meal 
and become epimastigotes again [18, 42].  
The acute phase, usually not fatal, is followed by the 
chronic and asymptomatic phase, during which parasite 
multiplication seems to be controlled by the host immune 
system [15, 43]. The parasite is not completely eliminated, 
being able to persist in low numbers lifelong [15, 36, 43]. 
Human hosts will then serve as reservoirs [15, 43].  
Replication control and persistence of the parasite during 
the chronic phase is mainly due to T cell-mediated immunity 
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regulating the anti-T. cruzi immune response [15, 44].  
During cruzi-trypanosomiasis, Treg cells are present but 
their role in the control of the immune system is still 
controversial. Contrary to African trypanosomes, T. cruzi is 
an obligate intracellular parasite [36]. Thus, the immune 
response induced by an extracellular or by an intracellular 
parasite will probably trigger different regulatory 
mechanisms. Vitelli-Avelar et al. [44] were the first to 




 Treg cells in 
whole blood obtained from chronic (asymptomatic) T. 
cruzi-infected human patients. Later, these results were 







 Treg cells found in chagasic patients 





 Treg cell subsets expressing 
characteristic Treg cell markers, such as FoxP3
+
, GITR and 
CTLA-4 were found in the heart of T. cruzi infected mice 
associated with host resistance and control of parasite 
replication. When treated with anti-GITR antibody to block 
the suppressor activity of Treg cells, mice suffered from 
increased parasitism, myocarditis and mortality alongside 
with upregulated production of TNF-α, in comparison with 
controls [47]. Taken together, these results suggest that Treg 
cells might play a role in the immune response against T. 
cruzi infection reducing extensive effective immune 
response, ultimately controlling the infection.  
 
C.   Malaria 
Plasmodium spp. are parasitic protozoan responsible for 
causing malaria in the tropical and sub-tropical regions 
worldwide [48]. Currently, five species of the genus 
Plasmodium are known to infect between 300 and 600 
million humans every year, resulting in approximately 1 
million deaths [49]. In developing countries such as 
sub-Saharan African countries, the majority of the infections 
are caused by P. falciparum responsible for cerebral malaria, 
the most malignant form of the disease, which in most cases 
leads to death due to severe anemia and neurological 
problems [21, 48]. Malaria caused by P. vivax, known as 
relapsing malaria, and P. ovale, together with P. falciparum, 
are the most widespread across continents. However, after a 
deep analysis Lysenko and Bejaev [50] report the presence of 
P. ovale mainly in the sub-Saharan Africa and the islands of 
the western pacific. Other publications also report its 
presence in New Guinea and the Philippines (as reviewed by 
Collins & Jeffery [51]). P. malariae and P. knowlesi have 
also been associated with cases of malaria in Southeast Asia 
[52]. In most cases and with the exception of a few regions, 
the acute form of the non-falciparum malaria is mild and can 
be controlled, persisting a chronic infection of low 
parasitemia [53].  
The life cycle of Plasmodium spp. parasites is complex 
with different stages both in the anopheline vector and in the 
human host. In general, the infection starts when a female 
mosquito of the genus Anopheles feeds on a vertebrate host, 
inoculating sporozoites into the host bloodstream [18]. 
Sporozoites, the infectious form of the parasite, rapidly reach 
the liver, invade and multiply within the hepatocytes, 
originating the schizonts. Schizonts rupture releasing 
merozoites into the blood stream [48] that easily adhere to 
and infect red blood cells (RBC). Inside RBC the parasite 
expands exponentially, developing into the trophozoite stage 
[38], divide asexually into mature schizonts (erythrocytic 
schizogony), which in turn rupture the RBC and the 
merozoite form is released into the blood stream, 
consequently infecting other RBC, perpetuating the infection 
[18]. Some of the merozoites forms may develop into male 
and female gametocytes, the sexual erythrocytic stages. 
When ingested by a female mosquito, these forms fuse in the 
mosquito stomach to form motile zygotes that invade the 
midgut and develop into oocysts that after rupture release 
new sporozoites. The sporozoites migrate to the salivary 
glands and when the anopheline female takes up a blood meal 
on a vertebrate host, the parasite is transmitted continuing the 
life cycle [18, 48, 54].  
Pathogenesis in malaria occurs after merozoites develop in 
RBC and the release of RBC cellular content activates 
monocytes and macrophages [52]. Splenic and circulant 
monocytes and DC activate CD4
+
 Th1 effector cells [55, 56], 
which secrete pro-inflammatory cytokines, such as IFN-γ 
[57], TNF-α, IL-1β and IL-16 [58]. As with other protozoan 
parasites, host protection is rather ineffective, as Plasmodium 
parasites develop evasive mechanisms to hide from the 
immune system or subvert its mechanisms of action 
(reviewed by Coban et al. [59]), limiting adaptive immunity 
and memory acquisition. Furthermore, difficulties in 
understanding the disease are also related to external and 
extrinsic factors of the host itself which influence the level of 
pathogenesis, such as nutritional status [60], intestinal flora 
[57], age [55, 61, 62] and ethnicity.  







 T cell subset [57, 63], inducing tolerance 
and promoting homeostasis [64] through the production of 
anti-inflammatory cytokines IL-10 and TGF-β. T lymphocyte 
receptors (TLR) on nTreg cells might also be stimulated by 
Plasmodium lipopolysacharide agonists, such as 
glycosylphosphatidylinositol (GPI) or hemozoin-bound 
DNA [65], and P. falciparum erythrocytic membrane protein 
1 (PfEMP-1), presented by DC and macrophages [56]. 
Uncomplicated malaria by P. falciparum and P. vivax was 
also shown to induce changes in cell number and proportions 
of Treg cells and DC [66].  
In human malaria, the suppression of host protection is 
probably mediated by IL-10 [60]. IL-10 origin is still unclear, 
but most likely secreted by different peripheral blood 
mononuclear cells (PBMC), such as monocytes [49, 60], 
macrophages [52], naïve and effector CD4
+
 T and iTreg cell 





FoxP3-PBMC induced by P. 







 cells were only a very small contributing 
fraction. Scholzen et al. [68] hypothesized that Treg cells 
might be inducible by the self-regulating FoxP3-Th1 
IL-10-producing cells, a mechanism also observed in L. 
major-infection. TGF-β, other major suppressive cytokine is 
mainly secreted by nTreg cells [69] and macrophages [70]. 
nTreg cells have been shown to require DC TLR-9 
stimulation to be activated [71], but the role of this type of 
receptors remains controversial, probably due to single 
nucleotide polymorphisms (SNP) in pattern recognition 
receptors (PRR) such as TLR, which result in different 
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 T cells to express FoxP3 [66], 
through antigen presentation by immature DCs [65, 72] and 
monocytes [73]. It has been shown, however, that direct cell 
contact is not always necessary for activation of FoxP3 [73], 
which can gain regulatory function by stimulation from the 
circulating cytokines IL-2 and IL-10. There is a puzzling 
nomenclature for Treg cells in malaria, a problem which 
should be addressed, as it does not facilitate elucidative 
comparisons nor conclusions between studies. 
As with leishmaniasis, it is the balance between effector T 
cells and Treg cells that determines the severity of infection 
[68, 74]. Treg cells, while preventing excess inflammation 





 T cells, NKT and NK cells [65], resulting in 
prevalence of the parasite and disease [75]. Moreover, IL-2 
activated-Treg cells express high levels of B-cell lymphoma 
2 (Bcl-2), which in turn prevents apoptosis. Competition for 
IL-2 by Treg cells and memory T cells might be responsible 
for the dimension of memory cell population, delineating the 
severity of the symptoms [68]. Literature also indicates that 
in malaria infection nTreg cells possibly modulate both acute 
pro-inflammatory and Th1 memory responses [65].  
It appears that the cause for different manifestations of 
pathology is dependent on the levels of key cytokines present 
at specific stages of infection [58, 66]. If Treg cells are 
preferentially activated in the early stages of infection severe 
malaria is more likely to occur [74]; whereas if Treg cells are 
only activated in the latter stages of infection, effector 
mechanisms are able to eliminate more infected RBC, 
resulting in lower parasitaemias and suppressing 
inflammation at later stage [60]. In the last case, severe forms 





 Treg cells have been shown to lower IFN-γ 
production [76]. Depletion of CD25
high
 cells, of which the 
majority are Treg cells, protects mice from experimental 
cerebral malaria, whereas depletion of FoxP3
+
 cells did not, 
suggesting that Treg cells may suppress T cell responses of 
the host [77]. It is not the depletion of Treg cells the sole 
responsible for protection against cerebral malaria, probably 




 T cells that are 
retained even after treatment with anti-CD25 mAb. Cerebral 
malaria is inhibited by suppression of CD4
+





 Treg in mice infected with P. berghei [78]. 
Furthermore, they inhibit Th1 memory cells in a secondary 
challenge. However, it was shown that depletion of Treg cells 
resulted in increased effector T cell response against 
circumsporozoite protein in the liver stage, but failed to 
increase lasting memory [79]. In fact, the only individuals 
who seem to develop immune memory to Plasmodium 
infection are the ones living in endemic regions where they 
are repeatedly bitten [67, 80].  
More recently, Keswani & Bhattacharyya [81] have shown 
that Th17 cells which requires both TGF-β and IL-6 to 
differentiate, might play an important role in disease 
progression. IL-6 together with lower levels of TGF-β 






 iTreg cells, 
promoting differentiation of Th17 [81, 82]. During acute 
infection FoxP3
+
 Treg cells might be overwhelmed where 
IFN-γ and IL-10 co-secreting CD4
+
 effector cells likely 
auto-regulate themselves; however, if the parasite load is 
controlled, the Bcl-2 production decreases and FoxP3
+
 Treg 
cells suffer apoptosis [73]. 
 
D. Babesiosis 
Babesiosis is an emerging zoonotic disease caused by the 
intraerythrocytic protozoan from the genus Babesia [17]. 
This parasite has a worldwide distribution and is transmitted 
by ticks. B. microti is a major cause of a malaria-like illness 
in humans in several regions of North America and Europe 
[83, 84]. Its life cycle occurs between the white-footed field 
mouse, Peromyscus leucopus, and the deer tick Ixodes 
scapularis. Humans enter the cycle when bitten by infected 
ticks [85]. In Europe, B. divergens infections have been 
steadily increasing since the first report in 1957 [86-88]. 
Among other causes, the increase of human babesiosis cases 
reflects the augmented population of immunocompromised 
individuals susceptible to infection, to which Babesia 
infection is often lethal [89]. 
Babesia spp. infection starts when a tick feeds on a 
vertebrate host injecting sporozoites together with saliva. The 
sporozoites penetrate directly the RBC and by binary fission 
develop into merozoites that, after cell lysis, are released into 
the blood stream. Each merozoite is able to infect a new RBC 
and their size and location vary according to the Babesia and 
the host species. When a competent tick takes up a blood 
meal from an infected host, ingests babesia-infected RBC 
[89]. Some of these parasites will develop into gametocytes 
or strahlenkorper (‘ray bodies’) and fuse in the lumen of the 
digestive track originating zygotes [90]. The zygotes 
penetrate the midgut cells and transform into a motile stage, 
the ookinete. This stage migrates from the midgut and 
invades other tissues, including the ovaries resulting in 
transovarial transmission. After this point, Babesia will 
develop by asexual multiplication (sporogony), differentiate 
sporokinetes that invade the salivary glands, developing into 
sporozoites, the infectious stage for the vertebrate host [91]. 
The mechanisms of immunity to Babesia parasites are 
hypothesized to require both innate and adaptive immune 
responses; however, the cell-mediated immune response is 
considered the most important in reducing the multiplication 
of Babesia within the vertebrate host and, at the same time, 
probably leading to pathology [92]. To our best knowledge, 





Treg cells during Babesia infection, what contrasts with the 
information available for other protozoan parasites 
aforementioned. Jeong and colleagues [84] have shown that 







expand during the acute phase of disease in the spleen of B. 
microti-infected mice at 7 and 11 days post-infection, in 
comparison with control mice, facilitating the growth and 
survival of the parasite.  
In the future, it would be interesting to investigate and 




 Treg cells during the 
infection caused by Babesia spp.  
IV. CONCLUSIONS 
Infection by parasitic protozoan still represents major 
threats to human health worldwide, and the chronic phase of 
the diseases seems to be balanced in a tolerant state by Treg 
cells.  
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This work has given an overview about the function of 
Treg cells and highlighted the different regulatory 
mechanisms by which Treg cells may influence the 
homeostasis of the immune response, avoiding excessive 
immunopathology during protozoan infections. Amongst all 




 Treg cells are the best 
characterized to date. However, there is considerable 
controversy regarding the characteristics and functions of 
these cells when induced by protozoan infections, and there is 
no doubt that remains much to be learn for which more 
research must be undertaken. In the future, more could be 
gleaned from the long-term interaction between the 
mechanisms of immune regulation and the parasites. Several 




 Treg cells 
with the development and outcome of trypanosomiasis, 
leishmaniasis, malaria and babesiosis and the persistence of 
the respective parasites within the host. 
With an increasing number of immunocompromised 
individuals, the current insufficient medical treatments and 
ineffective prophylaxis alternatives, these infections have 
become of extreme importance. Great attention has also to be 
given to healthy immunocompetent individuals, as these 
protozoan infections are normally associated with the host’s 
inability to clear chronic infection, thus acting as possible 
reservoirs and contributing for the endemic populations. Any 
situation that will compromise the immune system can 
trigger disease reactivation and develop acute and 
symptomatic stages. Therefore, there is an urgent need to 
implement efficient strategies to prevent diseases caused by 
protozoan parasites.  
The understanding of these complex interactions would 
favor the design of immunomodulator drugs or vaccines and 
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